Photocure fundamentale forhold (PHO)

[kreinh]

https://www.roche.com/investors/updates/inv-update-2022-06-16

Merlin skriver på HO:

"Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options

En slik screening kan bety voldsom etterspørsel etter Cevira, siden screeningen vil avsløre skjulte tilfeller. Dermed er Cevira mer aktuelt enn noensinne."

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (101 likes)

@Rodjer

Ny klinikk oppført på Cysiew også ikveld.

2. @Savepig (63 likes)

@Savepig

https://twitter.com/HainanToday/status/1508743478196543490

3. @roblar (42 likes)

@roblar

Jeg tror vi skal gi DS minst ett år post covid med normalitet før vi dømmer han nord og ned. Greit nok at du ikke er fornøyd med kommunikasjonen ut fra selskapet, men det virker nesten som du vil at alle potensielle problemer skal adresseres før de oppstår. Tror selv ikke en ny CEO vil leve opp til en slik forventning.

Resten av topp 10:

4. @gabster (41 likes)

5. @kreinh (38 likes)

6. @TyrionIV (12 likes)

7. @Quadruple (12 likes)

8. @myk (12 likes)

9. @rosk82 (9 likes)

10. @theroger (8 likes)

Gratulerer!

[TekBot]

Photocure Collaborations at EAU Support the Latest Advancements in Bladder Cancer Technology

High-definition blue light cystoscopic imaging showcased at the European
Association of Urology (EAU) Congress, Amsterdam

…

Vis børsmeldingen

Press release - Oslo, Norway, July 5, 2022: Photocure ASA, The Bladder Cancer
Company, announces that its collaborations with capital equipment providers
support the most advanced technologies including recent blue light system
upgrades. These collaborations were most recently showcased at this year’s
European Association of Urology (EAU) Congress July 1-4, 2022, in Amsterdam. At
this Congress, Photocure’s commercial teams focused on making this first
opportunity to be present “in person” count in order to support its customers
and the Urology society.

The EAU saw the first public demonstration of Karl Storz’s new and improved Blue
Light System to be used with Photocure’s Hexvix[®] product for the detection of
NMIBC*. This new photodynamic diagnostics (PDD) system based on the new light
source POWER LED SAPHIRAT from KARL STORZ was featured on both companies’
exhibition stands at the EAU Congress, including on the Photocure Bladder Cancer
Awareness Bus.

Delegates could discover for themselves how the “IMAGE1 ST SAPHIRA[T]” system
improves visualization of bladder cancer via demonstrations and hands on
experience. Manufactured and soon to be commercialized by KARL STORZ, the new
Blue Light system is the next generation of equipment, designed to improve the
Blue Light experience and provide next-level visualization.

“Photodynamic diagnostics (PDD) is an important cornerstone of accurate
diagnosis and treatment of bladder cancer. This advancement in Blue Light
equipment will not only provide a better experience for our customers, but also
hopefully convince the remaining clinics of the benefits of this technology,”
commented Dr. Susanne Strauss, Vice President and General Manager, Europe at
Photocure. “We are proud to support our business partners in their equipment
launches and to co-create bladder cancer awareness initiatives to improve the
care of bladder cancer patients.” Strauss concluded.

“The new Blue Light System Powered by Saphira received significant attention and
praise in the U.S. at the American Urological Association congress in May” added
Geoff Coy, Vice President & General Manager North America. “With confidence
phase testing now complete, we expect roll-out of this high-definition system to
begin this month to raise the technology standard for Blue Light Cystoscopy in
the U.S., improve the experience of our customers, and to expand blue light
usage throughout North America.”

Photocure continues to partner with equipment providers to advance bladder
cancer awareness and understanding the science around blue light cystoscopy.
During the EAU congress, Photocure and Richard Wolf supported a scientific
session on Saturday, July 2, on the topic of “Photodynamic Diagnostics in
Bladder Cancer” within the “Technology developments never end!” section of the
program. Both companies also co-animated an exhibition area dedicated to the
benefits of Blue Light Cystoscopy (BLC[®]) using a high-definition system.

EAU as an in-person event once again provided Photocure’s European teams with
the opportunity to further collaborate with capital equipment providers to
advance the understanding and awareness of bladder cancer management. This year,
the Photocure booth featured the bladder cancer awareness bus parked in its
center. This bus, in partnership with the equipment suppliers, has already
brought bladder cancer awareness to several European countries and will continue
its voyage in 2023. When on tour, the bus provides hands-on BLC equipment
experience to healthcare professionals, and also aims to raise the awareness of
bladder cancer signs and symptoms for the general public.

*NMIBC: non-muscle invasive bladder cancer

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.
IMAGE1 ST and SaphiraT are registered trademarks of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to
Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[TekBot]

Photocure ASA – Share option grant

Oslo, Norway, 20 July 2022 - Photocure ASA (the “Company”) (OSE: PHO) has granted share options to employees and members of the board of directors.

A total of 715,028 share options, equal to 2.6% of total shares issued in the Company, were granted at an exercise price at NOK 114.89. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price.
…

Vis børsmeldingen

Out of the total grant, 710,500 options have been granted to employees. The options are granted in accordance with Photocure’s long term incentive program and the Company’s guidelines for remuneration of senior executives (the “Guidelines”), as approved by Photocure’s annual general meeting held 28 April 2022. The share option program and properties of the options are further described in the Guidelines.

Out of the total grant, 4,528 options have been granted to board members. The Company has implemented the option grant to the board of directors in accordance with the proposal by the nomination committee as resolved by the annual general meeting of Photocure on 28 April 2022. The share options to the members of the board of directors are granted at terms similar to the share option program for management (as described in the Guidelines), with adjustments as set out in the nomination committee’s proposal to the annual general meeting held on 28 April 2022.

Of the total grant the following was granted to primary insiders:

• Daniel Schneider, President and Chief Executive Officer, 130,000 options.
• Erik Dahl, Chief Financial Officer, 90,000 options.
• Geoffrey Coy, Vice President and General Manager of North America Operations, 65,000 options.
• Susanne Strauss, Vice President and General Manager of Europe Operations, 65,000 options.
• Grete Hogstad, Vice President Strategic Marketing & Business Development, 35,000 options.
• Anders Neijber, Vice President Global Medical Affairs and Clinical Development, 60,000 options.
• David Moskowitz, Head of Investor Relations, 25,000 options.
• Jan H. Egberts, Chairperson of the board, 1,312 options.
• Neal Shore, Member of the board, 804 options.
• Johanna Holldack, Member of the board, 804 options.
• Anders Tuv, Member of the board, 804 options.
• Anne Worsøe, Member of the board, 804 options.

Primary insider notifications pursuant to the market abuse regulation article 19 are attached.
For further information, please contact:

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Photocure Provides Update on Anticipated Commercial Availability of Karl Storz’s New Blue Light System in the United States

Oslo, Norway, July 27, 2022: Photocure ASA, The Bladder Cancer Company,
announces that it has been informed by Karl Storz that the U.S. launch of the
new high-definition blue light system has been delayed due to supply disruptions
…

Vis børsmeldingen

of certain capital equipment components. Based on current information, Photocure
now expects commercial availability of the upgraded blue light system in late Q3
2022.

The Company reports that five flexible blue light cystoscopy (BLC[®]) towers
were installed in the U.S. during the second quarter of 2022. While no rigid BLC
towers were available for placement during the second quarter, the demand for
blue light capital equipment remains strong.

“While the delayed launch of Karl Storz’s new blue light system is
disappointing, we continue to grow our revenue and market penetration with the
current installed base of BLC equipment, as awareness of the benefits of blue
light cystoscopy is growing with uro-oncologists,” said Dan Schneider, President
and CEO of Photocure. “The pre-launch demand from our customers for the new blue
light system continues to be robust, and we are looking forward to regaining
momentum with new accounts once this upgraded equipment becomes available. We
remain dedicated to serving our physician customers and their patients, and we
will keep our stakeholders informed on the launch timing.”

Important information:

This release contains certain forward-looking statements relating to inter alia
the business, financial performance and results of the Company and the industry
in which it operates. The terms “anticipates”, “assumes”, “believes”, “can”,
“could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”,
“plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case,
their negative, or other variations or comparable terminology are used to
identify forward-looking statements. Forward-looking statements concern future
circumstances and results and other statements that are not historical facts.
These statements are based on Photocure’s current expectations and are subject
to changes in circumstances. Any forward-looking statements contained in this
release, including assumptions, opinions and views of Photocure or cited from
third party sources, are subject to risks, uncertainties and other factors that
may cause actual results and events to be materially different from those
expected or implied by the forward-looking statements. Photocure cannot provide
any assurance that the assumptions underlying such forward-looking statements
are free from errors nor accept any responsibility for the future accuracy of
opinions expressed in this release or the actual occurrence of forecasted
developments.

This information is subject to the disclosure requirements pursuant to sections
5-12 of the Norwegian Securities Trading Act.

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.
IMAGE1 ST and SaphiraT are registered trademarks of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to
Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Savepig (74 likes)

@Savepig

Vi dundrer den ut!

2. @Rodjer (71 likes)

@Rodjer

Ny klinikk oppført på Cysview.

3. @roblar (44 likes)

@roblar

Jeg tror vi skal gi DS minst ett år post covid med normalitet før vi dømmer han nord og ned. Greit nok at du ikke er fornøyd med kommunikasjonen ut fra selskapet, men det virker nesten som du vil at alle potensielle problemer skal adresseres før de oppstår. Tror selv ikke en ny CEO vil leve opp til en slik forventning.

Resten av topp 10:

4. @gabster (30 likes)

5. @kreinh (29 likes)

6. @myk (23 likes)

7. @Hayen (20 likes)

8. @Quadruple (10 likes)

9. @rosk82 (9 likes)

10. @Snoeffelen (8 likes)

Gratulerer!

[Quadruple]

Norne tar ned kursmålet i forkant av kvartalspresentasjonen, men venter vekst:

"Post-pandemic comeback should be seen

We keep our Buy recommendation on PHO share at a lower TP of NOK 120/sh (140) ahead of 2Q report next week, where we expect solid growth to be seen in the figures.

Solid growth and near-zero EBITDA expected for 2Q

Photocure will release its 2Q22 report on August 10th. Our estimates stand at NOK 97m for revenues, which is 19% growth QoQ and 7% YoY. We expect that a better access to hospitals should lead to better sales figures for both Europe and the US after a rather sluggish start of the year. Currency should also play a big role due to the massive strengthening of the USD lately. Notably, this affects not only on the top line but costs as well. Therefore, we still see EBITDA marginally in the negative territory at NOK -2.5m for the closed quarter, as the company ramps up its sales efforts especially in Europe."

[TekBot]

Photocure ASA: Invitation to presentation of second quarter and first half year 2022 financial results

Oslo, Norway, 4 August 2022: Photocure ASA (Photocure, PHO: OSE) will announce
the second quarter and first half year 2022 financial results on Wednesday 10
August 2022 at 08:00 CEST and invites investors, analysts and the media to a
…

Vis børsmeldingen

presentation at Hotel Continental, Oslo, Norway at 14:00 CEST the same day.

The investor presentation will also be streamed live and be hosted by Daniel
Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and
questions can be submitted throughout the event.

The presentation is scheduled to conclude at 14:45 CEST.

The quarterly report and presentation will be published at 08:00 CEST and will
be publicly available at www.photocure.com. The streaming event is available
through https://channel.royalcast.com/landingpage/hegnarmedia/20220810_2/

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company
specializing in the discovery and development of innovative drugs for the
treatment of genitourinary tumors and other major diseases, announced that the
…

Vis børsmeldingen

multinational Phase III Clinical Trial of APL-1702 (Cevira[®]), a novel non
-surgical treatment of cervical high-grade squamous intraepithelial lesions
(HSIL), has successfully enrolled 402 patients in the study two months ahead of
schedule. Additionally, Photocure received a $1 million milestone payment from
Asieris related to the ongoing clinical development of Cevira.

APRICITY is a multicenter, prospective, double-blind, randomized controlled
Phase III study further evaluating the efficacy and safety of the integrated
drug-and light-delivery device Cevira[®] in the treatment of HSIL. The clinical
trial was approved by the National Medical Products Administration (NMPA) in
July 2020 and was conducted simultaneously at 65 sites in 8 countries including
China, Germany, Hungary and the Netherlands. The first patient was dosed in
November 2020.

Cervical cancer is the fourth most common cancer in women worldwide[1]. In 2020,
604,000 new cases and 342,000 deaths worldwide were attributed to cervical
cancer.[1,2 ]Current treatments of HSIL of the cervix are based on invasive
surgical interventions, compromising cervical competence and functionality.
Currently, no non-surgical approach is available for the treatment of
precancerous cervical lesions.

Read Asieris’ full press release here: https://asieris.com/asieris-multinational
-phase-iii-clinical-trial-for-the-non-surgical-treatment-of-hsil-has-completed
-enrollment/

1. Cervical cancer. Available from: https://www.who.int/health-topics/cervical
   -cancer

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
   Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality
   worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49

Note to editors:
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

About Cevira[®]:

Cevira is a breakthrough photodynamic drug-device combination product that is
being developed for non-surgical treatment of high-grade precancerous lesions of
the cervix. Cevira holds the potential to serve the high unmet medical need for
non-invasive treatment options for patients with HSIL in an outpatient setting,
especially for young women of reproductive age. Asieris Pharmaceuticals entered
into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the
worldwide development and commercialization of Cevira in July 2019. Cevira[®] is
a registered trademark of Photocure ASA, based in Oslo, Norway.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[Savepig]

Finfint å ha dette på plass til kvartalsrapport!

[TekBot]

Photocure ASA: Results for the second quarter of 2022

Oslo, Norway, 10 August 2022: Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 99.9 million in the second quarter of 2022
(Q1 2021: NOK 88.9 million), and a positive EBITDA of NOK 1.4 million (NOK 5.8
…

Vis børsmeldingen

million). Karl Storz’s new high-definition blue light system is expected to
become commercially available in the United States in late third quarter 2022,
which is in turn expected to accelerate the placement of rigid towers.

“We delivered 12% Hexvix/Cysview revenue growth and 9% unit growth in the second
quarter of 2022, despite delays in the new Karl Storz blue light system launch
and ongoing effects from Covid-19. The commitment of our commercial teams in
both the U.S. and in Europe enabled the business to significantly recover from a
difficult first quarter and achieve positive year over year growth with our base
business, despite the staffing shortages that continue to plague healthcare
systems around the world. While access to care has reopened, many hospital
systems now have stricter rules for non-essential personnel within the facility,
and limited staffing means less time for face-to-face customer engagement.
Nevertheless, in the second quarter of 2022, our U.S. business achieved the
highest unit sales volume in our history, and we continue to increase Cysview’s
penetration into the bladder cancer treatment market,” says Dan Schneider,
President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 100.6 million in the second
quarter of 2022 (NOK 90.4 million), and an EBITDA* of NOK 1.4 million (NOK 5.8
million). The Hexvix/Cysview revenues ended at NOK 99.9 million in the quarter
(Q2 2021: NOK 88.9 million), on higher unit sales in both North American and
Europe and a favorable net benefit from foreign exchange. The EBIT was NOK -4.6
million (NOK -0.2 million) and the cash balance at the end of the second quarter
2022 was NOK 273.1 million. The installed base of blue light cystoscopes in the
U.S. was 329 at the end of the second quarter, an increase of 41 towers or 14%
since the same period in 2021, including a total base of 58 flexible
cystoscopes, which grew 38% year over year.

“I am pleased to reiterate that demand for blue light cystoscopy (BLC[®])
continues to be very strong, and that new high-definition blue light equipment
from Karl Storz is anticipated by our accounts in both the U.S. and European
markets. Major capital equipment suppliers are highly aware of the need, and are
preparing to launch new upgraded blue light systems in Europe. These technology
upgrades are expected to improve the BLC experience for physicians, and we
believe that the use of high-definition towers will further accelerate demand
for Hexvix/Cysview. Our U.S. pipeline for new BLC towers remains robust, and we
continue to work with Karl Storz in preparation of the launch of the new blue
light system later this quarter,” Schneider adds.

With the new Karl Storz system anticipated to launch in the U.S. in late third
quarter of 2022, Photocure expects that the placements of new blue light rigid
towers will accelerate in the fourth quarter of this year. Meanwhile, the
company will continue to focus on increasing the use of Cysview in existing
accounts as well as placing flexible BLC equipment, for which installation
momentum has increased.

“We believe that the second half of this year has potential for some exciting
developments. With healthcare access now reopened and the new high-definition
blue light system expected to launch in the coming weeks, we are looking forward
to significantly expanding the base of blue light capital equipment and
accelerating the growth of our Hexvix/Cysview franchise,” Schneider concludes.

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
second quarter 2022 financial report on page 22.

Photocure will present its second quarter 2022 report on Wednesday 10 August
2022 at 14:00 CEST at Hotel Continental, Oslo, Norway. The investor presentation
will also be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl,
CFO.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20220810_2/

The presentation is scheduled to conclude at 14:45 CEST.

For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +47 45055000
Email: ed@photocure.com

David Moskowitz
Vice-President Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 10 August 2022 at 08:00 CET.

Kilde

[E24Bot]

Resultatreduksjon for Photocure: Ned 4,4 millioner kroner

Resultatreduksjon for Photocure: Ned 4,4 millioner kroner

[ufo]

Veldig godt intervju med DS

Salgsrekord for Photocure: Tør ikke gi guiding ennå

[TekBot]

Photocure appoints Anders Neijber, MD, PhD as Chief Medical Officer, Global Medical Affairs and Clinical Development

Press Release - Oslo, Norway, September 1, 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, today announced the appointment of Dr. Anders Neijber to
the position of Chief Medical Officer, Global Medical Affairs and Clinical
…

Vis børsmeldingen

Development and R&D, effective September 1, 2022.

Dr. Neijber is Photocure’s current VP Medical Affairs and Clinical Development
and joined the company in August 2021. He brings over 25 years of substantial
experience in the Uro-oncology area and successful leadership in the
pharmaceutical industry. He has had global and regional leadership roles, both
in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked
for Pfizer, AstraZeneca, Johnson & Johnson, Allergan, Ferring, and Novartis.
[Dr. Anders Neijber]

Dr. Neijber is a board-certified urologist, and has held an Assistant Professor
position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical
School, New Jersey.

“In the time that Anders has been with Photocure, he has proven his ability to
apply his extensive experience and deep knowledge in the field of Urology,
together with his business acumen in leading our Global Medical Affairs
strategy” said Dan Schneider, President and Chief Executive Officer of
Photocure. “As Photocure continues to grow and expand its global reach, Medical
Affairs will have an increasingly important role in navigating the complex
health-care environment. Anders will be able to provide a strategic approach
beyond addressing the heightened regulatory and compliance regulations, to
further build a Global Medical Affairs organization that will have a strong
foundation for future scalability and capability globally.”

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Savepig (94 likes)

@Savepig

Vi er vel mer eller mindre ferdigdebattert om ultimovacs i denne tråden…

2. @Rodjer (67 likes)

@Rodjer

Ny klinikk oppført på Cysview.

3. @myk (40 likes)

@myk

Eneste som betyr noe er top linje veksten, kostnadene blir konstante fremover i forhold til veksten som kommer. Slapp av dette blir bra og kjøp.

Resten av topp 10:

4. @rosk82 (32 likes)

5. @Hayen (29 likes)

6. @kreinh (25 likes)

7. @Snoeffelen (24 likes)

8. @Quadruple (20 likes)

9. @Bingo123 (19 likes)

10. @Truls2 (11 likes)

Gratulerer!

[TekBot]

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology

Press release - Oslo, Norway, September 8th, 2022: Photocure ASA, The Bladder
Cancer Company, is delighted to continue supporting the global launch activities
of the new and improved Blue Light Cystoscopy (BLC[®]) system to be used with
…

Vis børsmeldingen

Photocure’s product Hexvix[®] for the detection of bladder cancer. In Europe,
the photodynamic diagnostics (PDD) system based on the new light source POWER
LED SAPHIRAT from KARL STORZ was featured for the first time in an E-Masterclass
Webinar, hosted by both companies on September 6. This event was accompanied by
the leading experts in Urology in the field of Bladder Cancer.

Together with the experts from KARL STORZ and Photocure, Prof. Arnulf Stenzl,
Prof. Lukas Lusuardi, Dr. Param Mariappan and Prof. Morgan Rouprêt showcased the
new next-generation Blue Light system to the E-Masterclass participants. Over
400 registered delegates could see how the “IMAGE1 ST SAPHIRA[T]” system
improves visualization of bladder cancer via practical case studies.
Manufactured and commercialized by KARL STORZ, the new Blue Light system is the
next generation, improving the Blue Light experience and providing next-level
visualization.

“In the last months, I have had the opportunity to use the new Saphira light
source, which really ameliorates the quality of the procedure
significantly”, said Prof. Lukas Lusuardi, Professor of the Department of
Urology at Paracelsus Medical University (PMU) Hospital Salzburg, Austria. “The
quality of vision was exceptional - even in white light. With PDD and the new
POWER LED Saphira, I was very comfortable to make the resection and TURBT under
blue light, which was not the case before, I have to say. So especially with the
bipolar resection, I feel quite comfortable to perform the resection under the
blue light, just to be sure in the best possible way”, added Prof. Morgan
Rouprêt, full Professor (academic position) at APHP Sorbonne University, in the
Academic Urology Department of the Pitié-Salpétrière Hospital, in Paris, France.

“We are proud to be part of the ongoing launch of this exciting new high
-definition system in Europe,” commented Dr. Susanne Strauss, Vice President and
General Manager, Europe at Photocure. “Photodynamic diagnostics (PDD) is an
important cornerstone of accurate diagnosis and treatment of bladder cancer.
This advancement in KARL STORZ’s equipment will provide a better Blue Light
experience for our customers, as the overwhelmingly positive feedback from the e
-masterclass clearly shows,” Susanne Strauss concluded.

“PDD started in Germany, with the full commitment of KARL STORZ, and so it is a
pleasure for us to introduce the new IMAGE1 ST SAPHIRAT system in the E
-Masterclass on NMIBC with PDD,” said Paolo Cantù, Director Urology Global
Marketing at KARL STORZ. “The new light source POWER LED SAPHIRA[T] will allow
us to serve the needs of our healthcare partners, providing high image quality
in white light as well as in blue light for the detection and treatment of
bladder cancer. Together with the Photocure team we now make high-quality BLC
available to more patients worldwide”.

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.
SaphiraT is a registered trademark of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

About KARL STORZ
The medical technology company KARL STORZ was founded in 1945 in Tuttlingen,
Germany, and is an international leader in the world of endoscopy. Now in its
third generation, the family-owned company employs 8,300 people in 40 countries
worldwide. The company portfolio includes more than 15,000 products for human
and veterinary medicine. KARL STORZ stands for visionary design, precision
craftsmanship and clinical effectiveness. Sales for the fiscal year 2021
amounted to 1.97 billion euros. Production sites are located in Germany, the
USA, Switzerland and Estonia. Please find more information at: www.karlstorz.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[TekBot]

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Press release - Oslo, Norway, September 15, 2022: Photocure ASA (PHO: OSE), The
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) has communicated today on the inclusion of Hexvix[®] in the 2022 edition
…

Vis børsmeldingen

of the Lecheng Global Specialty Drug Insurance Specialty Drug List.

As a new specialty drug benefit plan developed under the guidance of the
government covering 40 domestic specialty drugs and 60 overseas specialty drugs,
the Lecheng Global Specialty Drug Insurance allows Hainan citizens access to
more advanced medical resources and comprehensive coverage of their medical
needs.

In December 2021, Hexvix received initial clinical use in the Boao Lecheng
International Medical Tourism Pilot Zone in Hainan Province when the first
prescription in China was issued at Hainan General Hospital, and the first
patient procedure was completed. Asieris received approval from the National
Medical Products Administration (NMPA) for Hexvix to be included in phase III
clinical trials in the first quarter of 2022 as well as a real-world clinical
data pilot study.

Asieris expects the incorporation of Hexvix into the Lecheng Global Specialty
Drug Insurance to help them explore innovative access models, so that innovative
drugs can be introduced into China and covered by commercial insurance earlier
and faster.

Read Asieris’ full media release here: Hexvix®, A Diagnostic Drug of Asieris, is
Now Covered by the 2022 Lecheng Global Specialty Drug Insurance - Asieris
Pharmaceuticals (https://asieris.com/hexvix-a-diagnostic-drug-of-asieris-is-now
-covered-by-the-2022-lecheng-global-specialty-drug-insurance/)

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Isreal. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[TekBot]

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

Press release - Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder
Cancer Company, announces the publication of first results from the Laser III
clinical study in the medical journal, European Urology. The study is part of a
…

Vis børsmeldingen

systematic program aimed at verifying the safe treatment of bladder tumors in
the outpatient setting. Laser III results demonstrate the non-inferiority of
outpatient laser-mediated destruction of bladder tumors in conjunction with blue
light cystoscopy (BLC[®]) and Hexvix[®] versus inpatient BLC TURBT* under
general anesthesia. Photocure has supported this program and the specific study
since 2016.

Laser III is a prospective, randomized, non-inferiority trial conducted in the
Capital Region of Denmark from 2016 to 2020 (NCT02886026). Patients with
histologically verified Ta low-grade bladder tumor recurrence were enrolled. A
total of 206 patients were randomized; 176 finished treatment and were available
for follow-up as per protocol. The first results, now published in European
Urology, evaluated 4-month non-inferiority of outpatient laser-mediated ablation
of recurrent Ta tumors with flexible cystoscopes under local anesthesia,
compared to TURBT under general anesthesia. Both the out-patient laser procedure
and TURBT procedure were performed under BLC-guidance. Four-month recurrence
-free survival was assessed as the primary endpoint with a predefined non
-inferiority criterion of 15%. Secondary outcome measures were pain during the
outpatient laser ablation, postoperative morbidity, postoperative complications,
and patient’s preference. The 12-month follow-up results are expected to be
presented in a second paper.
Four-month recurrence-free survival was 8% higher after laser-ablation of the
bladder tumor compared to TURBT, and the predefined noninferiority criterion was
met. The study authors conclude that laser intervention in the outpatient
setting is as good as TURBT with general anesthesia, and has less complications.

In addition, the paper also advocates the importance of enhanced cystoscopy to
mediate this practice change. As recommended by the guidelines, enhanced
cystoscopy should be used during surgical treatment of non-muscle invasive
bladder cancer to improve detection and reduce recurrence.

“The study outcomes clearly demonstrate that for patients with small low grade
stage Ta bladder tumors the procedure can be safely moved from the OR to the
office, thereby reducing the burden for patients stemming from general
anesthesia and cost related to hospital stays. Safety is the most important term
here. Our team find that blue light cystoscopy with Hexvix in the OPD support
the identification of small bladder tumors which therefore safely can be removed
with laser before they become too large for outpatient treatment.” said Dr.
Gregers G Hermann, the Lead Investigator of this study and Consultant Urologist,
MD, DM Sc, F.E.B.U., Dept. of Urology, Herlev/Gentofte hospital, Denmark.

“We expect to see more scientific studies investigating how some of the more
intensive procedures like TURBTs can be reduced, avoided, or made more bearable
for patients. In non-muscle-invasive bladder cancer especially, where most
patients are over 55 years old, research into reducing patient burden is of
great importance. We believe BLC with Hexvix/Cysview can help responsible
researchers in these efforts by minimizing the concern of uncertainty when it
comes to detecting the tumors,” said Dan Schneider, President and CEO of
Photocure.

Read the full publication here:
Outpatient Photodynamic Diagnosis–guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis–guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial - ScienceDirect

(Clinicaltrials.gov Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors - Full Text View - ClinicalTrials.gov)

*TURBT: Transurethral resection of bladder tumor

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[CanonBoy]

Denne var veldig positiv for flex og fremtidig bruk og utbredelse av systemet. Å behandle pasienter uten innleggelse på sykehus og ekstra bedøvelse vil være mye mer effektivt og kostnadsbesparende. Det må selvsagt gjennomføres flere studier, men dette lover godt for FBLC og utbredelse til mindre klinikker.

“The study outcomes clearly demonstrate that for patients with small low grade
stage Ta bladder tumors the procedure can be safely moved from the OR to the
office, thereby reducing the burden for patients stemming from general
anesthesia and cost related to hospital stays. Safety is the most important term
here. Our team find that blue light cystoscopy with Hexvix in the OPD support
the identification of small bladder tumors which therefore safely can be removed
with laser before they become too large for outpatient treatment.” said Dr.
Gregers G Hermann"

“Four-month recurrence-free survival was 8% higher after laser-ablation of the
bladder tumor compared to TURBT, and the predefined noninferiority criterion was
met. The study authors conclude that laser intervention in the outpatient
setting is as good as TURBT with general anesthesia, and has less complications.”

[TekBot]

Photocure ASA – Major shareholding disclosure

On 23 September 2022, Briarwood Chase Management LLC, via a private investment fund under its management, acquired 92,704 shares in Photocure ASA. Following which, Briarwood Chase Management LLC controls 4,113,097 shares in Photocure ASA, corresponding to 15.17% of the company’s outstanding share capital and voting rights. The shares in Photocure ASA are held through a private investment fund which is managed by Briarwood Chase Management LLC, whose Managing Member is Aalap Mahadevia.

This notification is made public pursuant to section 4-2 of the Norwegian Securities Trading Act.
…

Vis børsmeldingen

Kilde